Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|October 15, 2009
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerS Novello, G V Scagliotti, R Rosell, et al.
British Journal of Cancer|March 21, 2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyM D Michaelson, A X Zhu, D P Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitorsAnne G Gilg, Sandra L Tye, Lauren B Tolliver, et al.
Chemmedchem|December 13, 2017
[Carboxyl-11 C]Labelling of Four High-Affinity cPLA2α Inhibitors and Their Evaluation as Radioligands in Mice by Positron Emission TomographyMartin J Fisher, Lindsay McMurray, Shuiyu Lu, et al.
Molecules (Basel, Switzerland)|October 27, 2018
[O-methyl-11C]N-(4-(4-(3-Chloro-2-methoxyphenyl)-piperazin-1-yl)butyl)-1H-indole-2-carboxamide ([11C]BAK4-51) Is an Efflux Transporter Substrate and Ineffective for PET Imaging of Brain D₃ Receptors in Rodents and MonkeyJeih-San Liow, Cheryl L Morse, Shuiyu Lu, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2011
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerL Q M Chow, N Blais, D J Jonker, et al.
British Journal of Cancer|March 11, 2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA J Zurita, M Khajavi, H-K Wu, et al.
Cell Metabolism|May 16, 2020
Positive Reinforcing Mechanisms between GPR120 and PPARγ Modulate Insulin SensitivityVivian A Paschoal, Evelyn Walenta, Saswata Talukdar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 2018
Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus MonkeysMin-Jeong Kim, Stal S Shrestha, Michelle Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)H J M Groen, M A Socinski, F Grossi, et al.
Pageof 3